- Framework of problems / Rigourous
- Conflicts of interest or funding of included studies not assessed
- An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs
| Ref ID | 893 |
| First Author | T. Muka |
| Journal | ELIFE |
| Year Of Publishing | 2023 |
| URL | https://elifesciences.org/articles/85679 |
| Keywords |
Protocols Transparency COVID Oncology Risk of bias Disclosure Non-Cochrane reviews Low methodological quality |
| Problem(s) |
Reasons for excluding potentially eligible studies not provided Conflicts of interest or funding of included studies not assessed Risk of bias not incorporated into conclusions of review Low methodological (AMSTAR) quality No registered or published protocol |
| Number of systematic reviews included | 52 |
| Summary of Findings | From 52 included systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations indexed across PubMed and WHO COVID-19 up to November 2022. Only two reviews scored moderate to high methodological quality using AMSTAR-2, while the rest (43/52; 82.6%) were evaluated as low or critically low quality. Almost half of the included reviews (25/50; 48.0%) did not report a protocol; only 3 provided a list of excluded studies (5.7%) and just 4 reported on sources of funding of included studies (7.6%); an assessment of risk in individual studies when interpreting/discussing the results was only carried out in 8 reviews (15.3%). |
| Did the article find that the problem(s) led to qualitative changes in interpretation of the results? | Not Applicable |
| Are the methods of the article described in enough detail to replicate the study? | No |